LaMattina: Profit is key for pharma to prosper, survive

10/6/2013 | Forbes

The pharmaceutical industry must yield a profit to survive, prosper and innovate, John LaMattina writes in response to an article in the Journal of the American Medical Association about the cost of drugs. Drugmakers such as Merck are cutting costs, and the pharmaceutical industry has experienced significant consolidation over the past 15 years, LaMattina writes. Return on investment through the pricing of valued medicines is key for the industry's success, LaMattina writes.

View Full Article in:

Forbes

Published in Briefs: